Cardiovascular and Renal: Positive trial results demonstrate consistent renal and cardiovascular benefit in treating patients with moderate to severe renal deficiency with canagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor

https://www.mdmag.com/conference-coverage/asn-2019/credence-kidney-week